American Founder Mutation for Lynch syndrome: Prevalence estimates and implications

Cancer

Volumn 106, Issue 2, 2006, Pages 448-452

  Lynch, Henry T ^a,e   De La Chapelle, Albert ^b   Hampel, Heather ^b   Wagner, Anja ^c   Fodde, Riccardo ^c   Lynch, Jane F ^a   Okimoto, Ross ^a   Clark, Mary Beth ^a   Coronel, Stephanie ^a   Trowonou, Abdon ^a   Fu, Yun Xin ^d   Haynatzki, Gleb R ^a   Gong, Gordon ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TEXAS   (United States)

^e CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carrier; Colorectal carcinoma; Founder mutation; Lynch syndrome

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CANCER CONTROL; EXON; FAMILIAL CANCER; FOUNDER EFFECT; GENE; GENE DELETION; GENE MUTATION; GENEALOGY; HETEROZYGOTE DETECTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MISMATCH REPAIR GENE; MSH2 GENE; POLYMERASE CHAIN REACTION; POPULATION GROWTH; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; SCREENING;

COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; FEMALE; FOUNDER EFFECT; HETEROZYGOTE; HUMANS; INCIDENCE; MALE; MUTATION; PREVALENCE; UNITED STATES;

EID: 30744433609     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21624     Document Type: Article

References (15)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. International Agency for Research on Cancer. Globocan 2002. Available at URL: http://www-dep.iarc.fr/globocan/ [accessed September 22, 2004].
3. Vogelstein B, Kinzler KW, edsitors. The genetic basis of human cancer. New York: McGraw-Hill, 1998.
4. Lynch HT, de la Chapelle A. Genetic susceptibility to nonpolyposis colorectal cancer. J Med Genet. 1999;36:801-818.
5. Lynch HT, de la Chapelle A. Genomic medicine: hereditary colorectal cancer. N Engl J Med. 2003;348:919-932.
6. Wijnen J, van der Klift H, Vasen H, et al. MSH2 genomic deletions are a frequent cause of Lynch syndrome. Nat Genet. 1998;20:326-328.
7. Wijnen J, de Leeuw W, Vasen H, et al. Familial endometrial cancer in female carriers of MSHS germline mutations. Nat Genet. 1999;23:142-144.
8. Wagner A, Barrows A, Wijnen JT, et al. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet. 2003;72:1088-1100.
9. Nakagawa H, Hampel H, de la Chapelle A. Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat. 2003;22:258.
10. Lynch HT, Coronel SM, Okimoto R, et al. A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA. 2004;291:718-724.
11. Lin KM, Shashidharan M, Thorson AG, et al. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg. 1998;2:67-71.
12. Jagers P. Branching processes with biological applications. London: John Wiley & Sons, 1975.
13. U.S. Census Bureau. State and county quickfacts. Washington, DC: U.S. Census Bureau, Year. Available at URL: http://quickfacts.census.gov/qfd/ [accessed August 30, 2005].
14. Ries LAG, Eisner MP, Kosary CL, editors. SEER cancer statistics review, 1975-2002. Bethesda, MD: National Cancer Institute, year. Available at URL: http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005 [accessed August 30, 2005].
15. Guttmacher AE, Collins FS, Carmona RH. The family history - more important than ever. N Engl J Med. 2004;351:2333-2336.